A-Bio, a strategic investment firm established by the Malaysian government, has invested RM7 million ($1.8 million) in Clinipath Malaysia, one of the country’s leading pathology service providers.
Clinipath, wholly owned by Malaysian Genomics Resource Centre, said the investment by A-Bio will help it improve its IT infrastructure, expand laboratories in key locations, and develop new clinical tests.
